Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04661137
Title A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hackensack Meridian Health

multiple myeloma


Dexamethasone + Pomalidomide + Selinexor

Daratumumab + Dexamethasone + Selinexor

Carfilzomib + Dexamethasone + Selinexor

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.